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Abstract:
Purpose: RNA methylation eraser FTO and writer METTL3 play important roles in human
diseases by regulating gene expression. However, the potential of FTO and METTL3 as markers
in renal clear cell carcinoma (CCRCC) is still unknown. The purpose of this study is to
investigate differential expression of FTO and METTL3 in CCRCC vs. normal kidney tissues,
the association of FTO and METTL3 expression and methylation with and their interaction of
FTO and METTL3 expression in patient survival in CCRCC.
Method: FTO and METTL3 expression and methylation, the clinicopathologic data were
retrieved from a publicly accessed dataset of The Cancer Genome Atlas (TCGA) of 537 patients
with primary CCRCC. Survival analysis was performed using Kaplan-Meier survival curve and
multivariate cox regression model. Random-effects meta-analysis was applied to examine
differential expression of FTO and METTL3 in CCRCC vs. normal kidney tissues.
Results: Significant upregulation of FTO and METTL3 expression with 1.64 (95% CI: 1.431.89) and 1.17 (95% CI: 1.02-1.35) folds, respectively, were observed in CCRCC vs. normal
kidney tissues. Survival analysis showed that a superior survival was observed in both either
high FTO expression or low methylation, and either low METTL3 expression or high
methylation. The adjusted hazard ratios (HRs) were 0.67 (95% CI: 0.49-0.91, p=0.01) for high
vs. low FTO expression, 2.17 (95% CI: 1.38-3.42, p=0.0008) for high vs. low FTO methylation,
1.97 (95% CI: 1.45-2.68, p<0.0001) for high vs. low METTL3 expression, and 0.49 (95% CI:
0.31-0.79, p=0.003) for high vs low METTL3 methylation, respectively. A significant interaction
between FTO and METTL3 expression was observed in CCRCC patient survival (P=0.0328).
Conclusion: FTO and METTL3 expression and methylation are potential prognostic and
diagnostic markers in CCRCC.
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Introduction
RNA modification takes place in all living organisms and during this post-transcriptional
process, RNA nucleotides are modified. Up until now, over 100 different types of RNA
modifications have been identified, most of them occur in structured RNA such as tRNA and
rRNA, and they can also take place in mRNA, small and long non-coding RNAs.(LncRNAs)
[1]These RNA modifications are critical in modulating gene expression,[2] and consequently
impacting many essential biological processes.[3]Loss of regulation for RNA modifications
could cause relevant diseases.[4]

N6-methyladenosine (m6A) refers to the RNA modification during which the adenosine at the
nitrogen-6 position is methylated, and it is the most abundant modification in mRNAs and
LncRNAs. m6A has been demonstrated to be associated with a series of fundamental cellular
functions such as splicing,[5]stability,[6]translation,[7]circadian clock,[8]stem cell
differentiation[9], and innate immune response.[10] The abnormal m6A level has been reported
to link to diverse cancer types, such as leukemia, breast cancer, cervical cancer,
glioblastoma.[11]

m6A methylation is a dynamic and reversible modification through the orchestration of a set of
proteins “writers” (methyltransferase), “erasers” (demethylase) and “readers” (binding proteins).
[12] METTL3 is a major member of N6-adenosine-methyltransferase, which is encoded by
METTL3 gene on chromosome 14. The depletion of this enzyme results in significant reduction
in m6A level in mRNAs. [13] METTL3 has been reported to be associated with the pluripotency
and differentiation of embryonic stem cells (ESCs). [14] METTL3 has also been shown to
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participate in many fundamental biological processes, such as formation of the hematopoietic
system, T cell homeostasis, and neural stem cells differentiation. [14] It has been shown that the
METTL3 depletion in human myeloid leukemia cells is associated with increased differentiation
and apoptosis, which has been found to have delayed leukemia in experimental mice in vivo.
[15] Hua-Bing Li and colleagues have used METTL3 knockout mice to demonstrate that the lack
of METTL3 can affect the homeostasis and differentiation of T cell, and as a result, the T cells
would stay in the naïve state and lose the ability to respond to various stimuli.[10] The
upregulation of METTL3 has been found in many tumors, including liver cancer, breast cancer,
colorectal cancer, prostate cancer, etc.[16] It has been found that METTL3 can facilitate the
translation and expression of several critical oncogenes such as EGFR and TAZ in human
cancer cells, and hence can boost the growth and invasion of the cancer cells. The depletion of
METTL3 was observed to be related to remarkable reduction in growth, invasion of cancer cells,
and increased cell apoptosis has also been found. In contrast, the overexpression of METTL3 has
totally opposite effects on cancer cells.[17]

Fat mass and obesity-associated protein FTO is the first identified demethylase of m6A, which is
encoded by the FTO gene on chromosome 16. It has been demonstrated that the depletion of
FTO can result in the elevated level of m6A in mRNA, while the overexpression of FTO is
associated with decreased m6A level in human cells. [18] FTO has been found to be involved in
many physiological processes, such as transcriptome regulation and translation. [19] It has been
reported that FTO can target pre-mRNAs and act as an mediator in the process of alternative
splicing and 3’end processing. [5] At present, FTO is mostly considered to be associated with
obesity. It has been reported that, FTO, as an eraser of m6A, influences fat metabolism and
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mitochondrial content by regulating m6A level in liver cells. Decreased levels of m6A and
mitochondrial content with increased triglyceride (TG) accumulation have been observed along
with the high expression of FTO.[20] Since obesity is a risk factor for many cancers, the
association between FTO and cancers has attracted more and more attention recently.
Accumulated evidence has shown the overexpressed FTO in several cancers, such as AML,
endometrial cancer and gastric cancer. [19] It has been demonstrated to act as an oncogene in
several cancers, and FTO can also promote the growth and transformation of cancer cells.[19]

Recently, it has been reported that the cross-talk among m6A writers, readers and erasers can
modulate the growth and progression of cancers by controlling m6A level and gene expression in
cancer cells.[21] Another critical finding about m6A modification is that it can cause a structural
switch between double-stranded RNAs (dsRNA) and single-stranded RNAs (ssRNA) in the
secondary structure of RNAs.[22] m6A RNA modification inhibited the innate immune
response because it could cause the decrease of dsRNA, which acts as a stimulus to the innate
immunity.[23]Kidney cancer has been proven to be an immunogenic tumor and almost all kidney
cancers are associated with dysfunctional immunity. [24]The essential role that Innate immunity
has played in the development and progression of renal cell carcinoma has also been
identified.[25] Thus in this study, we aimed to investigate the association between RNA
methylation machinery FTO and METTL3 expression and their interaction, as well as their
promoter DNA methylation, with patient survival in kidney renal clear cell carcinoma, and to
further explore the correlations between both FTO and METTL3 and dsRNA and innate
immunity-related genes.
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Materials and Methods
Gene expression, methylation and clinicopathologic data
A CCRCC dataset from The Cancer Genome Atlas (TCGA), which is available at TCGA
provisional (www.cbioportal.org) was used. The upper quartile normalized RNA-Seq by
Expectation Maximization (RNA Seq V2 RSEM) data for FTO expression, the data for FTO
methylation (HM450), the data for dsRNA related factors expression (TLR3, TLR7, TLR8,
DDX58, IFIH1, NLRP3), the data for innate immunity related factors expression (CD274, CD80,
CD86, FCGR3A) of 537 patients were extracted. The clinicopathologic data was also retrieved
and combined with the gene expression and methylation data.

Differential expression of FTO and METTL3 in renal clear cell carcinoma vs. normal
kidney tissues
Gene expression dataset OncomineTM (www.oncomine.org) (ThermoFisher Scientific, MA,
USA) was used to compare the differential expression of FTO/METTL3 in CCRCC vs. normal
kidney tissues. The filters used for searching were Gene: FTO/METTL3, Analysis Type: Cancer
vs. Normal Analysis, Cancer Type: Kidney Cancer, Data Type: mRNA and Sample Type:
Clinical Specimen. Only renal clear cell carcinoma studies were included for the meta-analysis,
other types of kidney cancer, for example, renal papillary cell carcinoma were all excluded from
the analysis. Eight studies for FTO and seven studies for METTL3 were included in the final
analysis. Random-effects Meta-analysis was performed to investigate the differences in
FTO/METTL3 expression between CCRCC vs. normal kidney tissue. The fold-change values
from raw data were first transformed into Log2 fold-change to perform the Meta-analysis. The
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final Fold-change value was calculated by transforming the summarized Log2 fold change back
using formula: summarized Fold-change = 2summarized log2 Fold-change.

Statistical Analysis
SAS version 9.4 (SAS Institute, Inc., NC, USA) and R version 3.5.1 were used to perform the
statistical analysis. The overall survival time in months was calculated as the time from the first
diagnosis of CCRCC to the occurrence of death or the last follow-up. Kaplan-Meier survival
curve analysis (log-rank test) was first performed to test the association between the overall
survival and either FTO or METTL3 expression and methylation, respectively. All the 537
patients in the study were first divided into three groups based on the tertile distribution of the
gene expression and methylation, respectively. Then the pairwise tests were used to determine
which group is significantly different from one another for each variable. For the comparison
that didn’t have a significant result, these two groups would be combined as one group, then
comparing to the other group. At last, the patients have been categorized as High FTO group and
Low FTO group based on the expression of FTO, High FTO Methylation group and Low FTO
Methylation group based on the FTO methylation level, High METTL3 group and Low
METTL3 group based on the expression of METTL3, and High METTL3 Methylation group
and Low METTL3 Methylation group based on the METTL3 methylation level. The KaplanMeier survival curves have been constructed based on the final grouping described above. Then
the Multivariate Cox regression model was used to adjust for the potential confounders,
backward elimination strategy was used to obtain the final model. Wald test was performed to
test the interaction effect between gene FTO and gene METTL3. The HRs and 95% CI were
estimated after adjusting for age and tumor stage. The Spearman correlation analysis was
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performed to evaluate the correlation between the FTO/METTL3 expression and dsRNA related
genes, and also for the correlation between FTO/METTL3 expression and innate immunity
related genes. A p-value less than 0.05 was considered as significant.

Results
1. Clinicopathologic characteristics of CCRCC patients
The characteristics of the 537 patients with primary Renal Clear Cell Carcinoma (CCRCC) are
shown in table 1. The average age for the patients in this study was 61-years old with a range
from 25 to 90-years old. There were 64.4% male and 35.6% female in this study. Among the 530
patients whose race information was available, the majority of them were Caucasian (87.9%),
followed by African American (10.6%), and Asian (1.5%). The information for tumor stage was
known for 534 patients and 50.4% of them had stage I tumor, followed by stage III (23.4%),
stage IV (15.5%), and stage II (10.7%). During the follow-up, 33.0% of the CCRCC patients
deceased, with an average overall survival time of 44.3 months, ranging from 0 to 149.1 months.
Table 1. Clinicopathologic Characteristics of CCRCC Patients

Characteristic
Race

N

%

530

Asian

8

1.5

Black or African American

56

10.6

White

466

88.0

Sex

537

Male

346

64.4

Female

191

35.6

6

Tumor Stage

534

Stage I

269

50.4

Stage II

57

10.7

Stage III

125

23.4

Stage IV

83

15.5

Death

537

Yes

177

33.0

No

360

67.0

Age (years)

537

mean ± SD

Range

60.6±12.2

26-90

2. Correlations for FTO expression vs. METTL3 expression, FTO expression vs. FTO
methylation, METTL3 expression vs. METTL3 methylation
The spearman correlation test was performed to test the correlations. The results showed that
there was a significant negative correlation between the expression of FTO and METTL3 (p <
0.0001), the correlation coefficient was -0.32, with a 95% CI of (-0.39, -0.24); There was a
significant negative correlation between FTO expression and FTO methylation level (p <
0.0001), the correlation coefficient was -0.42, with a 95% CI of (-0.51, -0.33); There was also a
significant negative correlation between METTL3 expression and METTL3 methylation level (p
< 0.0001), the correlation coefficient was -0.31, with a 95% CI of (-0.40, -0.20). The scatterplots
with regression line and 95% boundary have been shown in figure 1.2.3.
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Figure 1. Correlation between FTO Expression vs. METTL3 Expression

Figure 2. Correlation between FTO Expression vs. FTO Methylation
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Figure 3. Correlation between METTL3 Expression vs. METTL3 Methylation

3. Association between FTO expression and overall patient survival in CCRCC
The log-rank test showed a significant difference in overall survival time between patients with
high or low FTO expression (log-rank p=0.003). The patients in high-level FTO group had a
superior overall survival comparing to the patients in FTO low-level group. The Kaplan-Meier
survival curves are shown in figure 4.

To adjust for the potential confounders, the Multivariate Cox regression model was constructed,
starting with the full model with all potential confounders (race, sex, tumor stage, age) available
in the dataset, then used the backward elimination strategy to arrive at a parsimonious model.
Three variables were retained in the final model (at p-value < 0.1), variable race and sex were
finally dropped. The result is shown in table 2. After adjusting for tumor stage and age, the
significant association between the FTO expression and death risk still remained. The high-level
9

FTO expression group decreased the risk of death comparing to the low-level group. (HR:0.67,
95% CI: 0.49-0.91, p=0.01)
Table 2. Association between FTO Expression and CCRCC Patient Survival

Variable

Death

FTO

HR

Low

Reference

High

0.67

95% CI

P

0.49-0.91

0.01

Tumor Stage
Stage I

Reference

Stage II

1.21

0.65-2.24

0.553

Stage III

2.38

1.59-3.58

<0.0001

Stage IV

6.75

4.60-9.89

<0.0001

Age

1.04

1.02-1.05

<0.0001
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Figure 4. Kaplan-Meier Survival Curves by FTO Expression

4. Association between FTO Methylation level and overall patient survival in CCRCC
The log-rank test was performed to test if there was any difference in patient survival between
the two groups of patients with different levels of FTO methylation. It turned out that there was a
borderline significant difference between the two groups (log rank p= 0.0682). Patients with
Lower FTO methylation level seemed to have better overall survival comparing to those with
higher FTO methylation level. The Kaplan-Meier survival curves constructed for these two
groups have been shown in figure 5.

In order to adjust for the potential confounders, the Multivariate Cox regression model was used,
similar to the model for FTO expression, the construction of the model also started with all
potential confounders inside (race, sex, tumor stage, age), and then backward elimination
strategy was applied to arrive at the final parsimonious model. Two variables (race, sex) were
11

dropped during this process, and three variables were retained in the final model (at p-value
<0.1). The results have been shown in table 3. After adjusting for tumor stage and age, there was
a significant association between the FTO methylation level and the patient survival in CCRCC.
The high-level FTO methylation group has relative elevated risk of death comparing to the lowlevel group. (HR: 2.17, 95% CI: 1.38-3.42, p= 0.0008)

Figure 5. Kaplan-Meier Survival Curves by FTO Methylation Level
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Table 3. Association between FTO Methylation and CCRCC Patient Survival

Variable

Death

FTO Methylation

HR

Low

Reference

High

2.17

95% CI

P

1.38-3.42

0.0008

Tumor Stage
Stage I

Reference

Stage II

1.46

0.65-3.31

0.3607

Stage III

3.21

1.84-5.62

<0.0001

Stage IV

10.34

6.08-17.60

<0.0001

Age

1.04

1.02-1.06

<0.0001

5. Association between METTL3 expression and overall patient survival in CCRCC
The log-rank test was performed for the two groups of patients based on the differentiated
METTL3 expression level. The significant difference in patient survival has been observed
between the two groups (p <0.0001), patients with higher METTL3 expression have inferior
overall survival compared to those with lower METTL3 expression, which is opposite to the
association between FTO expression and the overall survival. The Kaplan-Meier survival curves
constructed for these two groups have been shown in figure 6.

To adjust for the potential confounders, the Multivariate Cox regression model was applied,
similar to the model for FTO expression, the construction of the model also started with all
potential confounders inside (race, sex, tumor stage, age), and then the final parsimonious model
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was obtained using the backward elimination strategy. Two variables (race, sex) were dropped
during this process, and three variables were retained in the final model (at p-value <0.1). The
result has been shown in table 4. After adjusting for tumor stage and age, there was a significant
association between the METTL3 expression level and the overall patient survival in CCRCC.
The elevated METTL3 expression has raised the risk of death for the CCRCC patients. (HR:
1.97, 95% CI: 1.45-2.68, p < 0.0001)

Figure 6. Kaplan-Meier Survival Curves by METTL3 Level
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Table 4. Association between METTL3 Expression and CCRCC patient survival

Variable

Death

METTL3

HR

Low

Reference

High

1.97

95% CI

P

1.45-2.68

< 0.0001

Tumor Stage
Stage I

Reference

Stage II

1.20

0.65-2.22

0.5682

Stage III

2.52

1.68-3.79

<0.0001

Stage IV

7.05

4.81-10.32

<0.0001

Age

1.03

1.02-1.05

<0.0001

6. Association between METTL3 methylation level and overall patient survival in CCRCC
The log-rank test was performed to test if there was any difference in patient survival between
the two groups of patients with different levels of METTL3 methylation. Kaplan-Meier showed a
significant difference between the two groups (log rank p=0.0004). Patients with high METTL3
methylation level have superior overall survival comparing to those with low METTL3
methylation level. The Kaplan-Meier survival curves constructed for these two groups have been
shown in figure 7.

In order to adjust for the potential confounders, the Multivariate Cox regression model was used,
similar to the model for METTL3 expression, the construction of the model also started with all
potential confounders inside (race, sex, tumor stage, age), and then backward elimination
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strategy was applied to arrive at the final parsimonious model. Two variables (race, sex) were
dropped during this process, and three variables were retained in the final model (at p-value
<0.1). The result has been shown in table 5. After adjusting for tumor stage and age, there was a
significant association between the METTL3 methylation level and patient survival in CCRCC.
The high-level METTL3 methylation group has relative reduced risk of death comparing to the
low-level group. (HR: 0.49, 95% CI: 0.31-0.79, p= 0.0008)

Figure 7. Kaplan-Meier Survival Curves by METTL3 Methylation Level
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Table 5. Association between METTL3 Methylation and CCRCC patient survival

Variable

Death

Mettl3 Methylation

HR

Low

Reference

High

0.49

95% CI

P

0.31-0.79

0.0031

Tumor Stage
Stage I

Reference

Stage II

1.44

0.64-3.26

0.379

Stage III

2.59

1.47-4.55

0.001

Stage IV

8.67

5.14-14.63

<0.0001

Age

1.04

1.02-1.06

0.0003

7. Effects of FTO-METTL3 Interaction on Patient Survival in CCRCC
Wald test was performed to explore the interaction effect of FTO-METTL3 on patient survival in
CCRCC. Patients have been divided into two groups based on the median distribution of FTO
expression, and then also have been categorized into two groups based on the median
distribution of the METTL3 expression. There were 266 patients in the Low FTO group, with the
FTO expression ranging from 327.91 Reads Per Kilobase of transcript per Million mapped reads
(RPKM) to 2349.60 RPKM, comparing to the 267 patients in the High FTO group, with the FTO
expression ranging from 2350.79 RPKM to 6053.67 RPKM. For the two METTL3 groups, there
were 266 patients in the Low METTL3 group, with the METTL3 expression ranging from 36.73
RPKM to 437.52 RPKM, compared to the 267 patients in the High METTL3 group, with the
METTL3 expression ranging from 438.51 RPKM to 1499.30 RPKM. The Wald test result has
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shown a significant interaction between the FTO expression and METTL3 expression with the
adjustment of age and tumor stage. (W2=4.5559, P=0.0328) The stratified result for FTO and
METTL3 has been shown in table 6.
Table 6. Stratified Hazard Ratios for FTO and METTL3

Strata

Death
HR

95% CI

FTO High vs. Low at Low METTL3

1.15

0.71-1.88

FTO High vs. Low at High METTL3

1.97

1.45-2.68

HR

95% CI

METTL3 High vs. Low at Low FTO

2.19

1.38-3.50

METTL3 High vs. Low at High FTO

1.10

0.71-1.70

8. Correlation between FTO expression and dsRNA related genes
Spearman Correlation results are shown in table 7. Significantly positive correlations were
observed between FTO and TLR3, TLR7, TLR8, DDX58, IFIH1, NLRP3. (all p<0.0001)
Correlation coefficients were 0.60 (95% CI: 0.54-0.65) for TLR3, 0.35 (95% CI: 0.27-0.42) for
TLR7, 0.31 (95% CI: 0.23-0.38) for TLR8, 0.35 (95% CI:0.28-0.43) for DDX58, 0.40 (95% CI:
0.32-0.47) for IFIH1, and 0.24 (95% CI: 0.16-0.32) for NLRP3.
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Table 7. Spearman Correlation between FTO Expression and dsRNA Related Genes

Gene

N

Correlation

95% CI

P

Coefficient
TLR3

533

0.60

0.54-0.65

<0.0001

TLR7

533

0.35

0.27-0.42

<0.0001

TLR8

533

0.31

0.23-0.38

<0.0001

DDX58

533

0.35

0.28-0.43

<0.0001

IFIH1

533

0.40

0.32-0.47

<0.0001

NLRP3

533

0.24

0.16-0.32

<0.0001

9. Correlation between FTO expression and innate immunity related genes
Spearman Correlation results are shown in table 8. Significantly positive correlations were
observed between FTO and CD80, CD86, FCGR3A. Correlation coefficients were 0.10 (95% CI:
0.02-0.19) for CD80 (p=0.0162), 0.17 (95% CI: 0.09-0.25) for CD86 (p<0.0001), 0.23 (95% CI:
0.15-0.31) for FCGR3A (p<0.0001). While significantly negative correlations were observed
between FTO and CD274. Correlation coefficients was -0.09 (95% CI: -0.17, 0.00) (p=0.0498).
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Table 8. Spearman Correlation between FTO Expression and Innate Immunity Related Genes

Gene

N

Correlation

95% CI

P

Coefficient
CD274

533

-0.09

-0.17, 0.00

0.0498

CD80

533

0.10

0.02, 0.19

0.0162

CD86

533

0.17

0.09, 0.25

<0.0001

FCGR3A

533

0.23

0.15, 0.31

<0.0001

10. Correlation between METTL3 expression and dsRNA related genes
Spearman Correlation results are shown in table 9. Significantly negative correlations were
observed between METTL3 and TLR3, TLR7, TLR8, DDX58, IFIH1, NLRP3. (all p<0.0001
except for NLRP3 p=0.02) Correlation coefficients were -0.40 (95% CI: -0.46, -0.32) for TLR3,
-0.28 (95% CI: -0.36, -0.20) for TLR7, -0.23 (95% CI: -0.31, -0.15) for TLR8, -0.25 (95% CI:0.33, -0.17) for DDX58, -0.18 (95% CI: -0.26, -0.10) for IFIH1, and -0.10 (95% CI: -0.18, -0.02)
for NLRP3.
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Table 9. Spearman Correlation between METTL3 Expression and dsRNA Related Genes

Gene

N

Correlation

95% CI

P

Coefficient
TLR3

533

-0.40

-0.46, -0.32

<0.0001

TLR7

533

-0.28

-0.36, -0.20

<0.0001

TLR8

533

-0.23

-0.31, -0.15

<0.0001

DDX58

533

-0.25

-0.33, -0.17

<0.0001

IFIH1

533

-0.18

-0.26, -0.10

<0.0001

NLRP3

533

-0.10

-0.18, -0.02

0.02

11. Correlation between METTL3 expression and innate immunity related genes
Spearman Correlation results are shown in table 10. Significantly negative correlations were only
observed between METTL3 and CD86, FCGR3A. Correlation coefficients were -0.19 (95% CI: 0.27, -0.11) for CD86 (p<0.0001), -0.20 (95% CI: -0.28, -0.12) for FCGR3A (p<0.0001).
Table 10. Spearman Correlation between METTL3 Expression and Innate Immunity Related
Genes

Gene

N

Correlation

95% CI

P

Coefficient
CD274

533

0.04

-0.05,0.12

0.3749

CD80

533

0.02

-0.06,0.11

0.6094

CD86

533

-0.19

-0.27, -0.11

<0.0001

FCGR3A

533

-0.20

-0.28, -0.12

<0.0001
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12. Differential expression of FTO in CCRCC vs. normal kidney tissues
The summary result of fold change in FTO expression in CCRCC comparing to normal kidney
tissues from random effect Meta-analysis has been shown in table 11. Eight studies have met the
including criteria described above in the method section, and fold-change, p-value, t-statistics,
number of carcinoma samples, number of normal samples were extracted from these studies to
perform the random-effects Meta-analysis. All of these eight studies have an upregulation of
FTO expression in CCRCC comparing to that in normal kidney tissues, with fold-change greater
than 1. the summary FTO expression from the random-effects Meta-analysis across these eight
studies showed 1.64 folds upregulation in CCRCC compared to that in normal kidney tissues,
with 95% CI ranging from 1.43 to 1.89. The forest plot has been shown in Figure 8.
Table 11. Random Effects Meta-analysis of Differential FTO Expression in CCRCC vs. Normal
Kidney Tissues

Study

Fold-

P-value

t-statistics

Ncase

Nnormal

1.787

1.30E-06

5.884

26

5

2.235

9.06E-10

7.635

23

23

1.682

4.22E-06

5.267

27

11

change
Yusenko Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Jones Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Beroukhim Renal
Non-Hereditary Clear Cell Renal Cell
Carcinoma vs. Normal
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Hereditary Clear Cell Renal Cell Carcinoma

1.688

6.08E-07

6.635

32

11

1.659

0.116

1.623

24

3

1.694

0.005

3.031

9

9

1.213

0.07

1.754

14

3

Clear Cell Renal Cell Carcinoma vs. Normal

1.263

0.089

1.436

10

10

Summary Fold-change (95% CI)

1.64 (1.43, 1.89)

vs. Normal
Higgins Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Lenburg Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Cutcliffe Renal
Clear Cell Sarcoma of the kidney vs. Normal
Gumz Renal

Figure 8. Forest Plot for Random Effects Meta-analysis of Differential FTO Expression in CCRCC
vs. Normal Kidney Tissues

Overall Fold-change of FTO = 2

summarized log2 Fold-change

= 1.64 (1.43 -1.89)
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13. Differential expression of METTL3 in CCRCC vs. normal kidney tissues
The summary result of fold change in METTL3 expression in CCRCC comparing to normal
kidney tissues from random effect Meta-analysis has been shown in table 12. Seven studies were
included, and fold-change, p-value, t-statistics, number of carcinoma samples, number of normal
samples were extracted from these studies to perform the random-effects Meta-analysis. All of
these seven studies have an upregulation of METTL3 expression in CCRCC, comparing to that
in normal kidney tissues, with fold-change greater than 1. The summary METTL3 expression
from the random-effects meta-analysis across these seven studies showed 1.17 folds upregulation
in CCRCC compared to that in normal kidney tissue, with 95% CI ranging from 1.02 to 1.35.
The forest plot has been shown in Figure 9.
Table 12. Random Effects Meta-analysis of Differential METTL3 Expression in CCRCC vs.
Normal Kidney Tissues

Study

Fold-

P-value

t-statistics

Ncase

Nnormal

1.26

0.322

0.49

26

5

1.09

0.036

1.86

23

23

1.18

0.051

1.73

27

11

1.29

0.007

2.77

32

11

change
Yusenko Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Jones Renal
Clear Cell Renal Cell Carcinoma vs. Normal
Beroukhim Renal
Non-Hereditary Clear Cell Renal Cell
Carcinoma vs. Normal
Hereditary Clear Cell Renal Cell Carcinoma
vs. Normal

24

Lenburg Renal
Clear Cell Renal Cell Carcinoma vs. Normal

1.05

0.159

1.04

9

9

1.07

0.162

1.02

14

3

Clear Cell Renal Cell Carcinoma vs. Normal

2.22

0.003

3.18

10

10

Summary Fold-change (95% CI)

1.17 (1.02, 1.35)

Cutcliffe Renal
Clear Cell Sarcoma of the kidney vs.
Normal
Gumz Renal

Figure 9. Forest Plot for Random Effects Meta-analysis of Differential METTL3 Expression in
CCRCC vs. Normal Kidney Tissues

Overall Fold-change of FTO = 2

summarized log2 Fold-change

= 1.17 (1.02 -1.35)

Discussion
In this study, we demonstrated that patient survival in renal clear cell carcinoma (CCRCC) is
associated with the FTO and METTL3 machinery. We found that patients with high FTO level
have superior overall survival compared to those with low FTO level. The association remained
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significant after adjusting for age and tumor stage. This result suggests high FTO level has
played a protective role during the prognosis of CCRCC patients. This effect has also been
proven by the association between FTO methylation level and the patient survival in CCRCC. It
has been shown that higher level of FTO methylation was associated with borderline
significantly worse survival in CCRCC. After adjusting for the age and tumor stage, a significant
difference was observed. A negative correlation has also been found between FTO level and
FTO methylation level. All of the evidence above points to the fact that FTO is acting as an antitumor factor in the CCRCC progression.

Previous studies showed that FTO might play totally different roles in the progression and
prognosis of different types of cancers. Xu D and colleagues found that among gastric cancer
patients, highly expressed FTO is associated with poor survival and cancer occurrence.[26]While
another study has found that FTO can act as a tumor inhibitor in CCRCC through a novel FTO‐
PGC‐1α signaling axis.[27]The reason for the distinct roles FTO has played in different cancers
is still unclear, and the complicated mechanism under this dynamic process still needs further
exploration.

Since almost all kidney cancers are documented to be associated with immune dysfunction,
[28]and recently, m6A modification has been demonstrated to be associated with the regulation
of innate immune systems,[29] we tried to investigate the association between FTO and CCRCC
patient survival from the immune level.
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It has been found that m6A modification can cause a structural switch from double-stranded
RNA (dsRNA) to single-stranded RNA in the secondary structure of RNA, [22]since dsRNA can
trigger the activation of innate immunity, the decreased amount of dsRNA resulting from this
switch would result in downregulated response by innate immunity.[23] It has been proven by
Katalin and colleagues that RNA with m6A modified will not activate toll-like receptors TLR3,
TLR7, and TLR8, which are important TLR family members used to recognize pathogens by
innate immune system. The m6A modification has been demonstrated to inhabit the activation of
DCs. The secretion of cytokine and activation marker such as CD80, CD86 has been observed to
be suppressed by m6A.[29]In this study, we found there was significantly positive correlation
between FTO expression and TLR3, TLR7, TLR8, which is consistent with the findings from
previous studies, since FTO acts as a demethylase in m6A, higher FTO expression is associated
with lower m6A level, and as a result, more TLR receptors will be activated. Significantly
positive correlation was also observed between FTO expression and CD80, CD86, which
suggested that FTO can improve the activation and maturity of DCs. Instead, significantly
negative correlation was observed between FTO expression and CD274(PD-L1), which
suggested that higher FTO expression is associated with lower expression of checkpoint
inhibitor. PD-L1 has been considered to act as suppressors for anti-tumor immune response and
are critical in tumor progression, and it has been demonstrated to have reliable effects on treating
many advanced cancers.[30] The significantly positive correlation was also observed between
FTO and DDX58, IFIH1. These two genes encoded two essential innate immune receptors, RIG1 and MDA5, which also have been demonstrated as dsRNA detectors.[31] The result is
consistent with the findings that m6A can switch the structure of secondary RNA from doublestranded to single-stranded.
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Based on all the evidence above, it is reasonable that high FTO level is associated with superior
patient survival in CCRCC. Acting as eraser in m6A modification, FTO can remove the m6A
from RNA, which will cause the increase in the amount of dsRNA, and as a stimulus for innate
immunity, the immune response will be improved for CCRCC patients with high FTO level.

On the opposite, since METTL3 acts as a methylase in m6A modification, it is expected that
METTL3 will have an opposite effect on patient survival in CCRCC. The results from this study
is exactly the same as expected. Patients with higher METTL3 expression are associated with
inferior overall survival, the association remained significant after adjusting for age and tumor
stage. The association between METTL3 methylation level and patient survival also have
demonstrated that METTL3 acts as an unfavorable marker in the progression of CCRCC. The
association remained significant after adjusting for age and tumor stage. A significantly negative
correlation was also found between the METTL3 expression level and METTL3 methylation
level. Based on all the evidence above, METTL3, on the opposite of FTO, is playing an
offensive role in the progression of CCRCC.

As opposite to FTO, significantly negative correlation was observed between METTL3
expression and TLR3, TLR7, TLR8, DDX58, and IFIH1, which is consistent with the theory of
RNA structure switch by m6A, and the activation of innate immunity as described above. Acting
as the writer in m6A, high METTL3 level will produce more m6A modified RNA, coupled with
diminished dsRNA, and result in less activation of dsRNA sensors and TLR receptors. There
were also significantly negative correlations between METTL3 and CD80, FCGR3A, which
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suggested inhibited innate immune response by METTL3. The result is supported by another
study which has found the depletion of METTL3 can result in upregulated interferon related
response and as a result, inhibit viruses infection.[32] However, no significant correlation was
found between METTL3 level and anti-tumor immune inhibitor PD-L1. Since m6A is a dynamic
process, and it has been demonstrated to be able to regulate gene expressions through various
pathways, which are still not totally understood at present, further investigations of the
complicated mechanisms are needed.

Based on the opposite roles FTO and METTL3 played in the m6A modification process and also
in CCRCC patient survival, at last, we also want to know whether there was an interaction
between these two genes when they take effects on the prognosis of CCRCC. A study published
last year has reported that the cross-talk among m6A writers, readers and erasers can regulate
cancer growth and progression. They found that m6A methylase METTL14 and m6A
demethylase ALKBH5 could regulate each other’s level and also suppress m6A reader YTHDF3
to determine the m6A level in target genes. [33] Similarly, our study also found a significant
interaction between FTO expression and METTL3 expression in CCRCC patient survival after
adjusting for age and tumor stage. From the meta-analysis, both FTO and METTL3 have been
shown upregulated in tumor in comparison with normal tissues, which suggested both of these
two genes have oncogenic functions.
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Conclusion
In summary, this study has demonstrated that epigenetic silencing RNA methylation machinery
FTO and METTL3 are associated with patient survival in CCRCC, they are also associated with
innate immunity response level. This finding suggests that machinery FTO and METTL3 are
potential prognostic and diagnostic markers for CCRCC, and further studies in how exactly this
machinery regulates the immune gene expression are still needed in order to design target
immunotherapy for CCRCC patients in the future.
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